UA77042C2 - Substituted 4-tetrahydroquinolines, use thereof as medicament, a medicament containing them - Google Patents

Substituted 4-tetrahydroquinolines, use thereof as medicament, a medicament containing them Download PDF

Info

Publication number
UA77042C2
UA77042C2 UA20040705310A UA20040705310A UA77042C2 UA 77042 C2 UA77042 C2 UA 77042C2 UA 20040705310 A UA20040705310 A UA 20040705310A UA 20040705310 A UA20040705310 A UA 20040705310A UA 77042 C2 UA77042 C2 UA 77042C2
Authority
UA
Ukraine
Prior art keywords
methyl
dichloro
tetrahydroisoquinolin
atoms
uphenyl
Prior art date
Application number
UA20040705310A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of UA77042C2 publication Critical patent/UA77042C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
UA20040705310A 2001-12-05 2002-11-20 Substituted 4-tetrahydroquinolines, use thereof as medicament, a medicament containing them UA77042C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10159714 2001-12-05
PCT/EP2002/012990 WO2003048129A1 (de) 2001-12-05 2002-11-20 Substituierte 4-phenyltetrahydroisochinoline, verfahren zu ihrer herstellung, ihre verwendung als medikament, sowie sie enthaltendes medikament

Publications (1)

Publication Number Publication Date
UA77042C2 true UA77042C2 (en) 2006-10-16

Family

ID=7708117

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040705310A UA77042C2 (en) 2001-12-05 2002-11-20 Substituted 4-tetrahydroquinolines, use thereof as medicament, a medicament containing them

Country Status (33)

Country Link
EP (1) EP1453810B1 (sr)
JP (1) JP4510457B2 (sr)
KR (1) KR20050044724A (sr)
CN (1) CN100497314C (sr)
AR (1) AR037620A1 (sr)
AT (1) ATE425968T1 (sr)
AU (1) AU2002356689B2 (sr)
BR (1) BR0214753A (sr)
CA (1) CA2469385A1 (sr)
CO (1) CO5580748A2 (sr)
DE (1) DE50213372D1 (sr)
DK (1) DK1453810T3 (sr)
EC (1) ECSP045138A (sr)
ES (1) ES2324528T3 (sr)
HR (1) HRP20040507A2 (sr)
HU (1) HUP0600854A2 (sr)
IL (1) IL162316A0 (sr)
MA (1) MA27147A1 (sr)
MX (1) MXPA04005343A (sr)
MY (1) MY157371A (sr)
NO (1) NO326650B1 (sr)
NZ (1) NZ533322A (sr)
OA (1) OA12740A (sr)
PE (1) PE20030726A1 (sr)
PL (1) PL369313A1 (sr)
PT (1) PT1453810E (sr)
RS (1) RS48004A (sr)
RU (1) RU2298003C2 (sr)
TN (1) TNSN04100A1 (sr)
TW (1) TWI281860B (sr)
UA (1) UA77042C2 (sr)
WO (1) WO2003048129A1 (sr)
ZA (1) ZA200403711B (sr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
DE102004046492A1 (de) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
DE102005001411A1 (de) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
ES2430569T3 (es) 2005-02-18 2013-11-21 Astrazeneca Ab Compuestos antibacterianos derivados de piperidina
US20080269214A1 (en) * 2005-03-04 2008-10-30 Astrazeneca Ab Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102006012545A1 (de) * 2006-03-18 2007-09-27 Sanofi-Aventis Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103819403B (zh) * 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
WO2018129556A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
MX363056B (es) * 2012-08-21 2019-03-06 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
CN105392483B (zh) 2013-04-12 2019-03-15 阿德利克斯公司 用于抑制磷酸盐转运的nhe3结合化合物和方法
CN103788084A (zh) * 2014-03-02 2014-05-14 湖南华腾制药有限公司 四氢异喹啉衍生物及其合成方法
WO2016013657A1 (ja) 2014-07-25 2016-01-28 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物
JP6903923B2 (ja) * 2016-01-22 2021-07-14 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物を有効成分として含有する医薬
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
KR20240090875A (ko) * 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물
IL303799A (en) * 2020-12-18 2023-08-01 Shanghai Jemincare Pharmaceuticals Co Ltd TETRAHYDROISOQUINOLINE COMPOUND IN SUBSTITUTE BENZOHETROCYCLE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951702A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
CN100436420C (zh) * 1999-11-03 2008-11-26 Amr科技公司 4-苯基取代的四氢异喹啉及其用于制备药物的用途
DK1246806T3 (da) * 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
DE10019062A1 (de) * 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren

Also Published As

Publication number Publication date
AR037620A1 (es) 2004-11-17
JP2005515205A (ja) 2005-05-26
TNSN04100A1 (en) 2006-06-01
EP1453810A1 (de) 2004-09-08
RU2298003C2 (ru) 2007-04-27
HK1072597A1 (zh) 2005-09-02
DK1453810T3 (da) 2009-07-20
HRP20040507A2 (en) 2005-08-31
WO2003048129A1 (de) 2003-06-12
ATE425968T1 (de) 2009-04-15
ES2324528T3 (es) 2009-08-10
RU2004120295A (ru) 2006-01-10
EP1453810B1 (de) 2009-03-18
OA12740A (en) 2006-06-30
CO5580748A2 (es) 2005-11-30
MA27147A1 (fr) 2005-01-03
NO20042158L (no) 2004-08-27
CA2469385A1 (en) 2003-06-12
PT1453810E (pt) 2009-05-27
ECSP045138A (es) 2004-08-27
MY157371A (en) 2016-06-15
TW200306190A (en) 2003-11-16
MXPA04005343A (es) 2004-09-27
AU2002356689A1 (en) 2003-06-17
PL369313A1 (en) 2005-04-18
AU2002356689B2 (en) 2008-05-15
IL162316A0 (en) 2005-11-20
CN100497314C (zh) 2009-06-10
RS48004A (sr) 2006-10-27
BR0214753A (pt) 2004-12-14
KR20050044724A (ko) 2005-05-12
TWI281860B (en) 2007-06-01
PE20030726A1 (es) 2003-09-30
DE50213372D1 (de) 2009-04-30
NO326650B1 (no) 2009-01-26
NZ533322A (en) 2006-02-24
HUP0600854A2 (en) 2007-02-28
ZA200403711B (en) 2005-06-09
JP4510457B2 (ja) 2010-07-21
CN1617856A (zh) 2005-05-18

Similar Documents

Publication Publication Date Title
UA126549C2 (uk) Композиція і спосіб для з'єднання позаклітинних доменів типу і та типу іі як гетерологічного химерного білка
Khalil-Manesh et al. Lead-induced hypertension: possible role of endothelial factors
UA129537C2 (uk) Сполука-коагоніст gip/glp1
HUE025013T2 (hu) Szulfonamid-származékok
UA129947C2 (uk) Спосіб застосування коагоніста gip/glp1 при діабеті
ES2750008T3 (es) Células madre mesenquimatosas modificadas genéticamente que expresan klotho
UA121662C2 (uk) Химерний інсектицидний білок, інгібіторний відносно лускокрилих шкідників
HU230380B1 (hu) N-Védett amino-hidroxi-adamantán-karbonsav és eljárás az előálllítására
UA121093C2 (uk) Конструкція, яка містить токсиген, що кодує пестицидний білок, і спосіб її застосування для знищення напівтвердокрилих шкідників
CN110381982B (zh) 与myomixer促进的肌细胞融合相关的组合物和方法
HU230679B1 (en) Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
UA124734C2 (uk) Антитіло проти с5 і його застосування
UA126656C2 (uk) Біспецифічна конструкція антитіла до psma і cd3, яке залучають t-клітини
UA114173C2 (uk) Пристрій та спосіб для проведення проточної цитометрії
HUE031616T2 (hu) N1-pirazol-spiroketon acetil-koenzim-A karboxiláz inhibítorok
UA76887C2 (uk) Сполука піперидину
UA129793C2 (uk) Антитіло до фактора згортання xi
UA118866C2 (uk) Химерний білок сті
UA128281C2 (uk) Одержання маїсу, стійкого до північної плямистості листя
UA130716C2 (uk) Тонке картування і підтвердження локусу qtl, відповідального за ознаки вмісту волокон і кольору оболонки насіння, і ідентифікація маркерів snp для маркер-опосередкованого відбору на ці ознаки в лінії каноли з жовтою оболонкою насіння (ysc) yn01-429 і в її лінії диференціювання
McDougall Jr By Eastern windows: the story of a battle of souls and minds in the prison camps of Sumatra
Brown The Tamans of the Upper Chindwin, Burma
UA108224C2 (uk) Терапевтичні сполуки, які модулюють тирозинфосфатазу з підвищеним вмістом в смугастому тілі, і пов'язані з ними способи застосування
KR20260049582A (ko) 약물의 제조에 있어서의 양성자 펌프 조절제의 용도
Stephen British Columbia